Currents News Staff
Vaccine maker Pfizer says its latest trial of the COVID-19 vaccine for children ages 5 to 11 showed it is safe and generated a “robust” antibody response.
The company says it plans to submit to the U.S. Food and Drug Administration for emergency use authorization soon.
According to a Pfizer spokesperson, there were no instances of myocarditis, a type of heart inflammation that’s linked with MRNA vaccines.
These are the first such results released for a U.S. COVID-19 vaccine in this age group.
The data hasn’t been peer-reviewed or published yet.